A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 161 participants.

Also called NCT05951192

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 161 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05951192
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05951192. Allocation not applicable; no masking; primary purpose treatment. Start 2023-07-01 (actual); primary completion 2024-02-14 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease
Acronym
ROQ-IT
Condition
Anemia
Condition
Renal Insufficiency, Chronic
Condition
Renal Anemia
Intervention (Drug)
Daprodustat
Lead sponsor
USRC Kidney Research (class: research network)
Collaborator
GlaxoSmithKline (class: industry)

Record details

Record id
cardio:ct-nct05951192
Content hash
ee660189e12aeeeee407bf648576517b224caa37169e5d8c90477d071ba87795